ABCC8抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P12256(ABCC8 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P12256(ABCC8 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The ABCC8 antibody targets the protein product of the ATP-binding cassette subfamily C member 8 (ABCC8) gene, which encodes sulfonylurea receptor 1 (SUR1). SUR1 is a regulatory subunit of ATP-sensitive potassium (KATP) channels, predominantly expressed in pancreatic β-cells, neurons, and other tissues. These channels link cellular metabolic status to membrane excitability, playing a critical role in insulin secretion regulation. ABCC8 mutations are associated with congenital hyperinsulinism, neonatal diabetes, and neurological disorders like DEND syndrome.

ABCC8 antibodies are essential tools for studying SUR1 expression, localization, and function in health and disease. They are widely used in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to investigate KATP channel dynamics, β-cell dysfunction in diabetes, and drug mechanisms (e.g., sulfonylureas, which bind SUR1 to stimulate insulin secretion). These antibodies also aid in diagnosing genetic disorders linked to ABCC8 variants.

Challenges in ABCC8 antibody development include SUR1's complex transmembrane structure and homology with other ABC transporters. Specificity validation via knockout controls is crucial to avoid cross-reactivity. Commercial antibodies often target epitopes in cytoplasmic domains (e.g., nucleotide-binding domains) or extracellular loops, with varying cross-species reactivity (human, mouse, rat). Advances in recombinant antibody technology continue to improve their precision for research and clinical applications.